$ News

Trevena (TRVN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Trevena: Q3 Earnings Snapshot

Trevena Reports Third Quarter 2024 Results and Provides Business Update

Trevena Executives Terminated but Remain as Advisors

Trevena Announces Receipt of Nasdaq Delisting Notification

Trevena Faces Nasdaq Delisting and Uncertain OTC Future

Trevena receives Nasdaq delisting notification

Trevena trading halted, news pending

Trevena Announces Reverse Stock Split

TRVN Stock Earnings: Trevena Beats EPS for Q2 2024

Trevena: Q2 Earnings Snapshot

Trevena Reports Second Quarter 2024 Results and Provides Business Update

Trevena GAAP EPS of -$0.23

Buy Rating Affirmed for Trevena Amid Strong TRV-045 Development Progress and Stable Financial Position

Trevena reports Q2 EPS (23c) vs. (69c) last year

Trevena announces 1-for-25 reverse stock split

Trevena Announces $2M Non-Dilutive Financing Tranche and Reduction in Outstanding Liabilities in Connection with Existing ex-US Royalty Financing

Trevena Announces Preclinical TRV045 Data Providing Insight Into Novel Mechanism of Analgesic Effect in Chronic Neuropathic Pain Model and Demonstrating Statistically Significant Anti-Seizure Activity in Epilepsy Models

Trevena announces preclinical data on TRV045 in two research collaborations